Short Interest in HilleVax, Inc. (NASDAQ:HLVX) Grows By 11.2%

HilleVax, Inc. (NASDAQ:HLVX - Get Free Report) was the target of a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 498,500 shares, an increase of 11.2% from the March 31st total of 448,200 shares. Currently, 2.8% of the company's shares are short sold. Based on an average daily trading volume, of 147,400 shares, the short-interest ratio is currently 3.4 days.

HilleVax Stock Up 2.7 %

NASDAQ HLVX traded up $0.36 during trading on Wednesday, reaching $13.56. 108,171 shares of the company's stock were exchanged, compared to its average volume of 136,389. The stock has a market cap of $674.20 million, a P/E ratio of -4.46 and a beta of 0.65. The company has a debt-to-equity ratio of 0.10, a quick ratio of 10.62 and a current ratio of 10.62. The company has a 50 day moving average price of $15.71 and a two-hundred day moving average price of $14.66. HilleVax has a 1 year low of $9.94 and a 1 year high of $20.22.

HilleVax (NASDAQ:HLVX - Get Free Report) last announced its quarterly earnings results on Wednesday, March 20th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.80) by $0.02. On average, equities research analysts anticipate that HilleVax will post -3.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a "buy" rating and set a $28.00 price target on shares of HilleVax in a report on Thursday, March 21st.

Insider Transactions at HilleVax

In other news, Director Aditya Kohli sold 6,000 shares of the firm's stock in a transaction on Friday, April 5th. The stock was sold at an average price of $14.44, for a total transaction of $86,640.00. Following the completion of the transaction, the director now directly owns 789,776 shares in the company, valued at $11,404,365.44. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, CFO Shane Maltbie sold 3,576 shares of HilleVax stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $14.93, for a total value of $53,389.68. Following the completion of the transaction, the chief financial officer now directly owns 40,656 shares in the company, valued at $606,994.08. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Aditya Kohli sold 6,000 shares of HilleVax stock in a transaction on Friday, April 5th. The shares were sold at an average price of $14.44, for a total value of $86,640.00. Following the completion of the transaction, the director now owns 789,776 shares of the company's stock, valued at $11,404,365.44. The disclosure for this sale can be found here. Insiders sold a total of 78,039 shares of company stock worth $986,464,242 over the last ninety days. Company insiders own 29.30% of the company's stock.

Institutional Trading of HilleVax

A number of hedge funds and other institutional investors have recently made changes to their positions in HLVX. Swiss National Bank increased its position in shares of HilleVax by 47.2% during the third quarter. Swiss National Bank now owns 31,200 shares of the company's stock worth $420,000 after purchasing an additional 10,000 shares in the last quarter. StepStone Group LP increased its position in shares of HilleVax by 22.2% during the third quarter. StepStone Group LP now owns 826,567 shares of the company's stock worth $11,117,000 after purchasing an additional 149,998 shares in the last quarter. Maven Securities LTD acquired a new stake in shares of HilleVax during the third quarter worth about $478,000. Federated Hermes Inc. increased its position in shares of HilleVax by 80.6% during the third quarter. Federated Hermes Inc. now owns 2,113 shares of the company's stock worth $28,000 after purchasing an additional 943 shares in the last quarter. Finally, Monashee Investment Management LLC acquired a new stake in shares of HilleVax during the third quarter worth about $1,480,000. Institutional investors and hedge funds own 86.42% of the company's stock.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.